Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
VulvovaginitisYeast InfectionYeast Infection VaginalCandidiasis, Vulvovaginal
Interventions
DRUG

Oral Encochleated Amphotericin B (CAMB)

lipid-crystal nano-particle formulation amphotericin B

DRUG

Fluconazole

Trial Locations (23)

11777

ProHEALTH Care Associates, LLC - Suffolk OB-GYN, Port Jefferson

23502

Tidewater Clinical Research, Inc., Norfolk

28144

PMG Research of Salisbury, LLC., Salisbury

28401

PMG Research of Wilmington, LLC, Wilmington

30092

Brighton Clinical Research Associates, Norcross

30328

Mt. Vernon Clinical Research - Wake Research, Atlanta

33012

Neostart Corporation dba AGA Clinical Trials, Hialeah

33161

Healthcare Clinical Data, Inc., North Miami

33180

South Florida Medical Research, Aventura

33414

Visions Clinical Research, Wellington

33461

Altus Research, Lake Worth

33603

Clinical Research of West Florida - Tampa, Tampa

34653

Advanced Research Institute Inc, New Port Richey

35205

Alabama Clinical Therapeutics, Birmingham

38305

Jackson Clinic, Jackson

43231

Complete Health Care for Women, Columbus

Study Center, Columbus

70006

Medpharmics, Metairie

78229

Clinical Trials of Texas, Inc., San Antonio

85032

Precision Trials, LLC, Phoenix

90057

National Research Institute - Wilshire, Los Angeles

02720

New England Center for Clinical Research, Inc., Fall River

08648

Lawrence OB/GYN, Lawrenceville

All Listed Sponsors
lead

Matinas BioPharma Nanotechnologies, Inc.

INDUSTRY

NCT02971007 - Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) | Biotech Hunter | Biotech Hunter